RhAPPcast: The IL23/IL17 Cascade and Implications in the Pathogenesis of PsA, PsO, and IBD

Amanda Mixon, PA-C, President of RhAPP, is joined by Christy Vath, PA-C, an expert in immunology and rheumatology, to explore the IL-23/IL-17 pathway and its impact on chronic inflammatory diseases. This episode of RhAPPcast dives into how the IL-23 and IL-17 cytokines drive inflammation in psoriatic arthritis, psoriasis, and inflammatory bowel disease, shedding light on how targeted therapies are reshaping treatment approaches.

IL-23 is a key driver of the inflammatory cascade, fueling Th17 cells to produce IL-17A and IL-17F. These cytokines contribute to inflammation in the skin, joints, and gut, making them critical therapeutic targets for autoimmune diseases. With an increasing number of IL-23 and IL-17 inhibitors available, selecting the right therapy for patients involves understanding their unique disease profiles.

The discussion highlights the immunologic link between psoriatic arthritis, psoriasis, and IBD, emphasizing how treatment selection can be tailored to address multiple disease domains. Real-world clinical insights provide a practical perspective on when to prioritize IL-23 inhibitors over TNF blockers and how IL-17A and IL-17F inhibition compares in terms of efficacy and safety. Understanding these mechanisms is essential for healthcare providers managing complex autoimmune conditions, particularly when considering long-term disease control and patient outcomes.

With evolving research and emerging therapies, rheumatology and gastroenterology providers must stay ahead of the latest advances in IL-23 and IL-17 inhibition.

For more expert insights and the latest advancements in rheumatology, download the RhAPP ACE App for valuable resources and clinical updates.